# MTX-241F

Source: https://onco.cc/drugs/mtx-241f/  
OnCo record `mtx-241f` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MTX-241F is an experimental small molecule from MEKanistic Therapeutics, in preclinical development for glioblastoma, diffuse intrinsic pontine glioma and brain metastases and other cancers.

## Summary

MTX-241F (MTX-241) is a small molecule (brain-penetrant) from MEKanistic Therapeutics. A brain-penetrant dual PI3K and EGFR inhibitor. Its furthest stage is preclinical development, for glioblastoma, diffuse intrinsic pontine glioma, brain metastases and primary brain tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Also known as: MTX-241
- Tags: pipeline
- Code: MTX-241F
- Modality: Small molecule (brain-penetrant)
- Mechanism: A brain-penetrant dual PI3K and EGFR inhibitor.

## Sources

- MEKanistic Therapeutics: mekanistic.com: https://www.mekanistic.com/pipeline.html
- MEKanistic Therapeutics: mekanistic.com: https://www.mekanistic.com/pipeline.html

## Connected records

- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [MEKanistic Therapeutics](https://onco.cc/companies/mekanistic-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/mtx-241f.json